JDOC vs. WDNA

Last updated Aug 4, 2026

JDOC (Jpmorgan Healthcare Leaders ETF) and WDNA (WisdomTree BioRevolution Fund) are both Health & Biotech Equities funds. JDOC is actively managed, while WDNA is passively managed. Over the past year, JDOC returned 23.57% vs 47.99% for WDNA. Their 0.66 correlation means they have sometimes moved together and sometimes differently. JDOC charges 0.65%/yr vs 0.45%/yr for WDNA.

Performance

JDOC vs. WDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Jpmorgan Healthcare Leaders ETF (JDOC) and WisdomTree BioRevolution Fund (WDNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, JDOC achieves a 4.29% return, which is significantly lower than WDNA's 15.67% return.

JDOC

• 1D: -0.50%
• 1M: -2.51%
• 6M: 2.15%
• YTD: 4.29%
• 1Y: 23.57%
• 3Y*: —
• 5Y*: —
• 10Y*: —
• ALL TIME*: 9.54%

WDNA

• 1D: 0.36%
• 1M: -7.65%
• 6M: 7.60%
• YTD: 15.67%
• 1Y: 47.99%
• 3Y*: 6.00%
• 5Y*: -4.72%
• 10Y*: —
• ALL TIME*: -3.41%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
JDOC Jpmorgan Healthcare Leaders ETF	$21.20K	$19.99K	$31.46K
WDNA WisdomTree BioRevolution Fund	$23.82K	$29.46K	$25.09K

JDOC vs. WDNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
JDOC Jpmorgan Healthcare Leaders ETF	4.29%	15.36%	-1.04%	7.92%
WDNA WisdomTree BioRevolution Fund	15.67%	22.68%	-14.18%	23.91%

Correlation

The correlation between JDOC and WDNA is 0.67, which is moderate. They have sometimes moved together and sometimes differently, sharing some price drivers without tracking each other closely.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.67
Correlation (All Time) Calculated using the full available price history since Nov 2, 2023	0.66

The correlation between JDOC and WDNA has been stable across timeframes, ranging from 0.66 to 0.67 - a consistent structural relationship.

JDOC vs. WDNA - Sectors Allocation Comparison

Sectors	JDOC	WDNA
Healthcare	100.0%	90.0%
Basic Materials	-	6.3%
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	3.7%
Energy	-	1.1%
Financial Services	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

JDOC vs. WDNA — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

JDOC

JDOC Risk / Return Rank: 63
JDOC Sharpe Ratio Rank: 65
JDOC Sortino Ratio Rank: 73
JDOC Omega Ratio Rank: 61
JDOC Calmar Ratio Rank: 65
JDOC Martin Ratio Rank: 51

WDNA

WDNA Risk / Return Rank: 78
WDNA Sharpe Ratio Rank: 78
WDNA Sortino Ratio Rank: 78
WDNA Omega Ratio Rank: 70
WDNA Calmar Ratio Rank: 91
WDNA Martin Ratio Rank: 73

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

JDOC vs. WDNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Jpmorgan Healthcare Leaders ETF (JDOC) and WisdomTree BioRevolution Fund (WDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	JDOC	WDNA	Difference
Sharpe ratio: Return per unit of total volatility	1.60	1.90	-0.29
Sortino ratio: Return per unit of downside risk	2.53	2.67	-0.14
Omega ratio: Gain probability vs. loss probability	1.28	1.31	-0.03
Calmar ratio: Return relative to maximum drawdown	2.44	4.12	-1.68
Martin ratio: Return relative to average drawdown	6.25	9.50	-3.25

JDOC vs. WDNA - Sharpe Ratio Comparison

The current JDOC Sharpe Ratio is 1.60, which is comparable to the WDNA Sharpe Ratio of 1.90. The chart below compares the historical Sharpe Ratios of JDOC and WDNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

JDOC vs. WDNA - Drawdown Comparison

The maximum JDOC drawdown since its inception was -20.87%, smaller than the maximum WDNA drawdown of -58.87%. Use the drawdown chart below to compare losses from any high point for JDOC and WDNA.

Drawdown Indicators

	JDOC	WDNA	Difference
Max Drawdown Largest peak-to-trough decline	-20.87%	-58.87%	+38.00%
Max Drawdown (1Y) Largest decline over 1 year	-9.68%	-11.70%	+2.02%
Max Drawdown (3Y) Largest decline over 3 years	—	-36.65%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-58.87%	—
Current Drawdown Current decline from peak	-3.07%	-25.54%	+22.47%
Average Drawdown Average peak-to-trough decline	-6.72%	-35.29%	+28.57%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.78%	5.06%	-1.28%

Volatility

JDOC vs. WDNA - Volatility Comparison

The current volatility for Jpmorgan Healthcare Leaders ETF (JDOC) is 4.64%, while WisdomTree BioRevolution Fund (WDNA) has a volatility of 6.56%. This indicates that JDOC experiences smaller price fluctuations and is considered to be less risky than WDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	JDOC	WDNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	4.64%	6.56%	-1.92%
Volatility (6M) Calculated over the trailing 6-month period	11.60%	17.18%	-5.58%
Volatility (1Y) Calculated over the trailing 1-year period	14.82%	25.49%	-10.67%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	14.69%	25.26%	-10.57%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	14.69%	25.03%	-10.34%

JDOC vs. WDNA - Expense Ratio Comparison

JDOC has a 0.65% expense ratio, which is higher than WDNA's 0.45% expense ratio.

Dividends

JDOC vs. WDNA - Dividend Comparison

JDOC's dividend yield for the trailing twelve months is around 0.85%, less than WDNA's 3.95% yield.

Position	TTM	2025	2024	2023	2022	2021
JDOC Jpmorgan Healthcare Leaders ETF	0.85%	0.89%	5.57%	0.15%	0.00%	0.00%
WDNA WisdomTree BioRevolution Fund	3.95%	4.57%	0.75%	0.80%	0.38%	0.10%

Frequently Asked Questions

Can I hold both JDOC and WDNA in my portfolio?

JDOC and WDNA have a correlation of 0.67, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, JDOC or WDNA?

WDNA has higher volatility (6.56%) compared to JDOC (4.64%). In terms of maximum drawdown, JDOC dropped -20.87% vs WDNA's -58.87%.

Which ETF is better, JDOC or WDNA?

On 1-year performance, WDNA leads with 47.99% vs 23.57% for JDOC. On fees, WDNA is cheaper at 0.45% per year. On volatility, JDOC has been the lower-risk option at 4.64%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, JDOC or WDNA?

Over the 1-year period, WDNA has performed better with a 47.99% return vs 23.57%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, JDOC or WDNA?

WDNA is cheaper with a 0.45% expense ratio, compared with 0.65% for JDOC.

Which ETF pays a higher dividend yield, JDOC or WDNA?

WDNA has the higher dividend yield at 3.95%, compared with 0.85% for JDOC.

What is the main difference between JDOC and WDNA?

They also come from different issuers: JPMorgan and WisdomTree. Their fees differ too: 0.65% for JDOC and 0.45% for WDNA.

Which has better risk-adjusted returns?

WDNA currently has the higher Sharpe Ratio (1.90 vs 1.60), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.